Skip to content
News Center
About Us Careers News Center Contact Us Legal Doing Business with Illumina Investors Illumina for Startups

Press Releases

Date Title
1 Oct. 2025 Illumina launches new business to accelerate technology and data-driven discovery
23 Sep. 2025 Illumina advances personalized cancer care with new pharma development partnerships
18 Sep. 2025 Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
3 Sep. 2025 Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
31 Jul. 2025 Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025
30 Jul. 2025 Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling
10 Jul. 2025 Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025
10 Jul. 2025 Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year
23 Jun. 2025 Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
10 Jun. 2025 lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics
29 May 2025 Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis
28 May 2025 Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies
26 May 2025 Illumina Comprehensive Genomic Profiling Test for Cancer Receives Regulatory Approval in Japan
14 May 2025 Illumina To Webcast Upcoming Investor Conference
13 May 2025 Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications
8 May 2025 Illumina Reports Financial Results for First Quarter of Fiscal Year 2025
1 May 2025 Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development
15 Apr. 2025 Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
10 Apr. 2025 Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025
25 Mar. 2025 Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
19 Mar. 2025 Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery
10 Mar. 2025 Illumina addresses recent developments in China
6 Mar. 2025 Illumina named to Dow Jones Best-in-Class Indices for sixth consecutive year and as a Sustainability Yearbook Member for fourth consecutive year
24 Feb. 2025 Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology
21 Feb. 2025 Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions
19 Feb. 2025 Illumina unveils first-of-its-kind spatial transcriptomics technology
18 Feb. 2025 Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference
6 Feb. 2025 Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2024
14 Jan. 2025 Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2024 and Provides Preliminary Outlook for Fiscal Year 2025
13 Jan. 2025 Illumina and NVIDIA collaborate to decode biology and propel precision health
13 Jan. 2025 Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples
9 Jan. 2025 Illumina to Announce Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 6, 2025
7 Jan. 2025 Illumina advances NovaSeq X Series, delivering single-flow-cell system, software upgrade, and new kits to enable multiomic applications
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see sapac.illumina.com/company/legal.html.

© 2025 Illumina, Inc. All rights reserved.